You are here

Approvals, Launches, and New Indications

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
First Drug Approved Under Agency’s LPAD Pathway
May Reduce the Need for Open-Heart Surgery
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Orphan Drug May Provide Complete Corneal Healing in Some Patients
Battle of the Auto-Injectors May Lead to Lower Costs for Patients